To include your compound in the COVID-19 Resource Center, submit it here.
Celldex disclosed in its 2Q11 earnings that in June it discontinued an open-label, U.S. Phase II trial comparing neoadjuvant therapy
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury